Research across Leukemia
Related studies from across the Leukemia family.
TKI plus chemotherapy achieves deep molecular remission in Ph+ leukemia case with diagnostic framework
One patient's leukemia remission offers clues for rare diagnosis
This systematic review with a case report describes a patient with Philadelphia chromosome-positive leukemia who achieved complete remission…
A patient with a rare leukemia achieved deep remission for 35 months. The case highlights how to tell apart two similar-looking blood cancer…
Imatinib achieves complete cytogenetic response in a pediatric patient with suspected chronic myeloid leukemia
Imatinib works for CML in child with high platelets
This case report describes a pediatric patient with isolated thrombocytosis who achieved a complete cytogenetic response to imatinib after f…
A child with high platelets and no response to standard therapy was found to have CML and responded to imatinib.
Venetoclax plus intensive chemo yields 63.79% ORR in relapsed/refractory AML meta-analysis
Venetoclax combo shows promise for hard-to-treat leukemia
A meta-analysis of 235 patients with relapsed/refractory AML found that venetoclax combined with intensive chemotherapy achieved a pooled ov…
For patients with relapsed AML, venetoclax plus intensive chemo led to a 64% response rate in a new analysis.
GSTO1 inhibition induces apoptosis in AML cells while LMRS model stratifies patient risk
New lipid metabolism markers help predict outcomes for leukemia patients
This guideline synthesizes in vitro and observational data regarding lipid metabolism in acute myeloid leukemia (AML). The findings identify…
Researchers identified a new way to group and predict survival for patients with acute myeloid leukemia using lipid metabolism patterns.
Low-dose ATG plus PTCy shows no significant difference in acute GVHD compared to standard regimens
Trial Shows New Treatment Strategy for Leukemia Stem Cell Transplant
This randomized trial of 407 patients with AML or MDS undergoing haploidentical transplant found that low-dose ATG plus PTCy did not signifi…
A new combination of medications may help patients recover blood cells faster after a stem cell transplant for leukemia or blood disorders.
AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life
New combinations show promise for older adults with myeloid leukemia
This systematic review and meta-analysis of 47 studies evaluated treatments for older adults with AML ineligible for conventional chemothera…
Combining specific drugs like venetoclax with other treatments may improve survival and quality of life for older adults with acute myeloid …
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML
Trial shows venetoclax combined with chemotherapy for AML
This clinical trial of 259 newly diagnosed patients with acute myeloid leukemia found a 90.3% composite complete remission rate using a 7-da…
A new clinical trial shows that a short 7-day course of venetoclax combined with chemotherapy can achieve high remission rates in AML patien…
Novel strategies aim to separate GVHD from GVL effects in allo-HCT for AML
Novel strategies aim to separate GVHD from GVL effects in leukemia patients
This narrative review explores novel therapeutic strategies to separate graft-versus-host disease (GVHD) from graft-versus-leukemia (GVL) ef…
A narrative review explores new ways to treat acute myeloid leukemia while managing side effects after stem cell transplants.
HMA-venetoclax yields 50% overall response rate in relapsed/refractory AML meta-analysis
Combination therapy shows response in relapsed leukemia
This systematic review and meta-analysis of 2289 adults with relapsed/refractory acute myeloid leukemia found that hypomethylating agents pl…
For adults with relapsed leukemia, combining two drugs led to a 50% response rate, offering a potential new option for a tough situation.
Antibody-based therapies offer potential efficacy and durability options for relapsed refractory acute myeloid leukemia patients
Review explores antibody therapies for relapsed acute myeloid leukemia
This narrative review examines antibody-based therapies for relapsed or refractory acute myeloid leukemia. The authors discuss potential eff…
A review looks at antibody-based therapies for patients with relapsed acute myeloid leukemia, comparing them to traditional treatment option…
Review of glycolytic metabolism in acute myeloid leukemia cells notes research scope and limitations
Scientists examine how sugar metabolism affects acute myeloid leukemia cells
This narrative review examines glycolytic enzymes and glycolytic metabolism within acute myeloid leukemia (AML) cells. The authors synthesiz…
This review looks at how glycolytic enzymes and metabolism impact acute myeloid leukemia cells, offering new insights into this serious bloo…
Scoping review examines imatinib gonadotoxicity in males with chronic myeloid leukemia or gastrointestinal stromal tumors
Young Men's Fertility at Risk with Common Cancer Drug Imatinib
This scoping review synthesizes evidence on imatinib effects in males with chronic myeloid leukemia or gastrointestinal stromal tumors. Twen…
• Imatinib harms sperm production more in younger men permanently • Helps doctors counsel teens and young adults before treatment • Not a tr…